Solventum (NYSE:SOLV) Price Target Raised to $82.00

Solventum (NYSE:SOLV) had its target price lifted by Mizuho from $70.00 to $82.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other analysts have also issued reports on SOLV. The Goldman Sachs Group boosted their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday. Bank of America increased their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company increased their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler raised their price target on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Stock Down 1.5 %

Shares of NYSE SOLV opened at $77.79 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum has a one year low of $47.16 and a one year high of $85.92. The stock has a market capitalization of $13.44 billion and a PE ratio of 28.29. The business’s fifty day moving average price is $73.25 and its 200-day moving average price is $70.39.

Institutional Investors Weigh In On Solventum

Hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in Solventum during the fourth quarter valued at $203,740,000. Hotchkis & Wiley Capital Management LLC purchased a new stake in Solventum during the third quarter valued at $125,488,000. Trian Fund Management L.P. increased its position in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares during the last quarter. Boston Partners purchased a new stake in Solventum during the fourth quarter valued at $110,378,000. Finally, Independent Franchise Partners LLP increased its position in Solventum by 105.0% during the fourth quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company’s stock valued at $105,904,000 after acquiring an additional 821,272 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.